# Imagion Biosystems, Inc.: Phase 2 study in HER2-positive Breast Cancer (70 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Imagion Biosystems, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) |
| NCT ID | NCT07885683 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | HER2-positive Breast Cancer |
| Intervention types | combination product |
| Target enrollment | 70 |
| Posted | 2026-10-21 |
| Planned start | 2026-11-30 |
| Event | Newly registered study |
| Event date | 2026-10-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07885683). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.